Research Intelligence
The Diffusion Index — Single-Cell
Single-cell RNA sequencing is the most advanced technology on the adoption curve after NGS itself. It has crossed the chasm. The novelty premium has collapsed. The floor is now visible — and it tells us exactly where spatial transcriptomics is heading.
In 2016, 155 out of every 1,000 scRNA-seq papers appeared in Nature, Science, or Cell. The 10x Chromium platform had just launched. Profiling thousands of cells simultaneously was still remarkable enough to earn a top-journal paper on its own. The field was in full innovator fever.
By 2026, that number has fallen to 3.8 per 1,000 — a 41× decline in ten years. Running a scRNA-seq experiment is now a standard step in almost any molecular biology study. The journals don’t reward it; they expect it.
At ~4 per 1,000, single-cell is approaching the same commoditized floor that NGS reached in 2016 (~0.6 per 1,000). It is the most important calibration point we have for predicting where spatial transcriptomics — currently at ~13 per 1,000 — will land over the next five to eight years.
2016
Peak year
155.2 per 1,000
41×
Decline peak→today
2016 → 2026
~4
Current score
per 1,000 — floor in sight
How many papers, and where they land
Annual single-cell RNA-seq papers split into three tiers — Nature / Science / Cell, the rest of the top-tier specialist journals (Tier 1+2), and everything else. The log view keeps all three visible; the widening gap is the dilution the curve below captures as a ratio.
Log scale — each line is a count, so all three tiers stay visible despite spanning four orders of magnitude. The gap between the lines is the dilution: top-3 output barely moves while total volume explodes. 2006–2025 (2026 partial year omitted).
Single-cell RNA sequencing — top-tier journal share over time
Papers per 1,000 scRNA-seq publications appearing in top-tier journals, 2013–2026. Shaded regions correspond to Rogers adoption curve phases. Based on 35,434 PubMed-indexed papers. Early years (faded dots) have fewer than 50 papers and should be read with caution.
Peak: 380.7 per 1,000 in 2017 · current (2026): 42.3 per 1,000 — entering Laggards
What was hot in Nature, Science & Cell
The 538 single-cell papers that reached the top three journals — the largest top-3 haul of any technology in the index. The dominant currency is the cell atlas: cataloguing which cell types and states exist in a tissue. Where NGS earned its premium for new methods, single-cell earned it for comprehensive maps — the same shift spatial would inherit a few years later.
Absolute counts — each block is a real paper. Every single-cell RNA-seq paper in Nature, Science, or Cell (2013–2025), by research theme — absolute counts. Themes classified by Claude (Haiku) from titles.
What the curve tells us
The 10x Chromium launch in 2016 is visible in the data.
The peak score of 155 per 1,000 coincides almost exactly with the commercial launch of the 10x Chromium platform. Before 2016, scRNA-seq required bespoke microfluidics or plate-based sorting — heroic, expensive, and publishable in top journals by default. The Chromium democratized access almost overnight. Within two years, the paper count tripled and the diffusion score began its sustained decline. Commercial platform launches don’t just accelerate adoption — they compress the adoption timeline by removing the technical barrier to entry. Xenium and CosMx are doing exactly the same thing to spatial today.
The chasm crossed between 2020 and 2022.
The score dropped from 62 in 2020 to 16 in 2022 — a 4× collapse in two years. This is the signature of a technology crossing Geoffrey Moore’s chasm: the early majority floods in, the paper count explodes (1,147 → 4,181), and top journals stop rewarding the method and start demanding the insight. By 2022, reviewers expected scRNA-seq data as a matter of course. Single-cell had become a prerequisite, not a finding.
The floor is near — but higher than NGS.
At ~4 per 1,000 in 2026, single-cell is approaching the commoditized floor. NGS settled at ~0.6 per 1,000 by 2016 — but scRNA-seq is unlikely to reach quite that level. The reason: single-cell experiments are intrinsically more analytically complex than bulk sequencing. A genuinely novel single-cell atlas of an undercharacterized tissue or disease can still earn a Nature paper in a way that a routine bulk RNA-seq run cannot. The floor will be real, but it will be higher — our estimate is 1–3 per 1,000, probably reached around 2027–2029.
Single-cell as a calibration point for spatial.
Spatial transcriptomics today (~13 per 1,000) is where single-cell was in 2021–2022. Single-cell took roughly three years to go from that score to near-floor. If spatial follows the same trajectory — compressed by faster commercial adoption — it could reach its floor by 2027–2029. The key variable is cost: scRNA-seq dropped to under $100 per sample faster than spatial is tracking. If spatial cost curves accelerate, the floor arrives sooner. If they don’t, the descent is slower but the endpoint is the same.
The three-curve comparison
NGS
Peak: 118/1k (2008)
Chasm: 2008–09
Floor: ~0.6/1k
● Complete
Single-cell
Peak: 155/1k (2016)
Chasm: 2020–2022
Floor: est. 1–3/1k
◕ Floor in sight
Spatial
Peak: 146/1k (2020)
Chasm: 2022–2024
Floor: TBD
◑ Mid-descent
See also: NGS Adoption Curve · Spatial Transcriptomics
What the sequencing was for
The application mix of single-cell RNA-seq papers, 2013–2025, normalized to 100% per year. Single-cell is overwhelmingly a research technology — but a translational wedge is forming.
Research
Translational
Normalized to 100% per year. Classified by Claude (Haiku) over 35,009 scRNA-seq papers into tech-specific buckets. 2013–2025.
Single-cell RNA-seq began as a methods-and-atlas endeavor — through 2017, method development and cell-atlas / developmental work were most of the field. Cancer and the tumor microenvironment have since become the dominant application (~32% in 2025), with immunology close behind.
Unlike cfDNA, single-cell is still about three-quarters research. But a translational wedge is forming: drug-discovery / target-ID and clinical / translational studies together rose from essentially zero to ~23% of output. That is the early signature of a discovery platform beginning to cross into application — roughly where the diffusion curve says single-cell now sits.
Who uses it for what
Single-cell’s application mix by region. Click regions to set the baseline and see which countries lean into atlases, immunology, and cancer, and which into the translational edge.
Click a region to add or remove it from the comparison. The Average column and the green/red deviations recompute for whatever set you pick — so you can, say, keep only two regions and see how they differ from each other.
| Application | Average 4 regions | |||||
|---|---|---|---|---|---|---|
| Research | ||||||
| Cell atlas / developmental | 15.0% | 20.9% +39% | 21.2% +41% | 24.3% +62% | 9.8% -35% | 14.9% |
| Immunology | 12.1% | 12.5% +3% | 14.9% +23% | 16.8% +39% | 10.8% -11% | 14.6% |
| Cancer / tumor microenvironment | 28.9% | 15.6% -46% | 17.9% -38% | 22.4% -23% | 39.0% +35% | 23.9% |
| Neuroscience | 5.4% | 7.9% +45% | 7.5% +37% | 5.7% +4% | 3.6% -33% | 5.7% |
| Methods / computational | 14.3% | 23.6% +65% | 20.0% +40% | 11.8% -18% | 8.3% -42% | 16.9% |
| Infectious disease / COVID | 4.8% | 6.3% +32% | 5.0% +4% | 3.7% -23% | 4.1% -15% | 5.8% |
| Translational | ||||||
| Drug discovery / target ID | 9.8% | 6.8% -31% | 7.0% -28% | 7.9% -19% | 12.1% +24% | 8.7% |
| Clinical / translational | 9.6% | 6.4% -34% | 6.5% -32% | 7.5% -22% | 12.2% +27% | 9.5% |
Each cell shows that application’s share within the region, and below it the deviation from the average of the selected regions (e.g. +49% = 1.49× that average). Greyed columns are excluded from the baseline. Cumulative over 34,232 classified papers with a parseable first-author affiliation; region assigned by keyword match.
Where the papers come from
Share of single-cell RNA-seq papers by first-author affiliation, 2015–2026. Parsed from 34,616 affiliations.
US institutions led single-cell RNA-seq through its first decade — roughly a third of first-author papers. China crossed the US in 2022 and reached 58% by 2025, the steepest national concentration of any platform in the index. The US share has more than halved since 2017, even as the field exploded in volume.
Methodology: 35,434 papers from PubMed matching “single-cell RNA sequencing” OR “scRNA-seq” OR “single-cell transcriptomics,” 2011–2026. Journal tiers: Tier 1 = Nature, Science, Cell; extended Tier 1+2 includes Nature Methods, Nature Biotechnology, Nature Medicine, Nature Genetics, Nature Communications, Nature Cell Biology, Genome Biology, eLife, Cell Genomics, and other high-impact specialist journals. Diffusion score = top-tier papers / total papers × 1,000. Early years (2011–2015) have fewer than 50 papers and should be interpreted with caution. Data computed via scripts/fetch-singlecell.ts + scripts/compute-singlecell-diffusion.ts.